Patent · US Active

Proteins with high immunoreactivity and method for their production

US7820410B2 · kind B2 · utility

6Cited by

7References

5Claims

0Family size

Assignee

Scintec Diagnostics · CH

Inventors

Ivan Benes · Forch, CH
Silke Thomsen-Bosslet · Berlin, DE

Key dates

Filing date	Aug 1, 2007
Grant date	Oct 26, 2010
Priority date	—
Expiry date	Aug 1, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of >81%, preferably >90%. The inventive monoclonal antibodies are produced using a fluidized bed reactor in conjunction with a conventional protein-chemical purification method or preferably with a purification method involving less column chromatography. The monoclonal antibodies thus produced are suitable, in gamma-irradiated form, e.g. Tc-99m labeled, for the in vivo diagnosis of inflammatory diseases and bone marrow metastases. In alpha- or beta-irradiated form, e.g. astatine or Re-188 or Y-90 labeled form, the inventive monoclonal antibodies can be used, for example, in the treatment of leukemia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.